Noninvasive detection of PD-L1 on circulating tumor cells in patient blood samples
Author:
Affiliation:
1. Independent Researcher, Mercer Island, WA 98040, USA
Publisher
Future Medicine Ltd
Subject
Cancer Research,Oncology,General Medicine
Link
https://www.futuremedicine.com/doi/pdf/10.2217/fon-2018-0150
Reference29 articles.
1. Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
2. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
3. Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
4. PD-1 blockade induces responses by inhibiting adaptive immune resistance
5. Nivolumab plus Ipilimumab in Advanced Melanoma
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. An ultra-thin silicon nitride membrane for label-free CTCs isolation from whole blood with low WBC residue;Separation and Purification Technology;2022-09
2. Liquid biopsy zur Individualisierung der Therapie beim fortgeschrittenen Harnblasenkarzinom;Aktuelle Urologie;2021-12-07
3. Establishing peripheral PD-L1 as a prognostic marker in hepatocellular carcinoma patients: how long will it come true?;Clinical and Translational Oncology;2020-05-27
4. Current and future applications of liquid biopsy in nonsmall cell lung cancer from early to advanced stages;European Respiratory Review;2020-02-12
5. The current role and future directions of circulating tumor cells and circulating tumor DNA in urothelial carcinoma of the bladder;World Journal of Urology;2018-10-26
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3